Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age

NCT06740630 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06740630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06740630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Recruiting
Start date
January 10, 2025
Completion date
May 17, 2027
Enrollment
1,840 (estimated)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

chickenpox